about
Critical role of the Toll-like receptor signal adaptor protein MyD88 in acute allograft rejectionAlloantibody production is regulated by CD4+ T cells' alloreactive pathway, rather than precursor frequency or Th1/Th2 differentiation.The innate immune system in allograft rejection and tolerance.A signature of maternal anti-fetal rejection in spontaneous preterm birth: chronic chorioamnionitis, anti-human leukocyte antigen antibodies, and C4dCXCL10 and IL-6: Markers of two different forms of intra-amniotic inflammation in preterm labor.Loss of transgene following ex vivo gene transfer is associated with a dominant Th2 response: implications for cutaneous gene therapy.Maternal floor infarction/massive perivillous fibrin deposition: a manifestation of maternal antifetal rejection?Role and mechanism of action of complement in regulating T cell immunity.Detection of anti-HLA antibodies in maternal blood in the second trimester to identify patients at risk of antibody-mediated maternal anti-fetal rejection and spontaneous preterm delivery.Exogenous IFN-gamma ex vivo shapes the alloreactive T-cell repertoire by inhibition of Th17 responses and generation of functional Foxp3+ regulatory T cellsSingle time point immune function assay (ImmuKnow) testing does not aid in the prediction of future opportunistic infections or acute rejection.IL-17A mediates early post-transplant lesions after heterotopic trachea allotransplantation in MiceIL-17A and IL-2-expanded regulatory T cells cooperate to inhibit Th1-mediated rejection of MHC II disparate skin grafts.Pathogenesis of chronic allograft rejection.Natural killer receptor repertoires in transplantation.Gene expression profiling in acute allograft rejection: challenging the immunologic constant of rejection hypothesis.Effector mechanisms in transplant rejection.Optimal modes and targets of gene therapy in transplantation.CD8 T-cell recognition of acquired alloantigen promotes acute allograft rejection.Bronchiolitis obliterans syndrome: the Achilles' heel of lung transplantation.Chronic inflammation of the placenta: definition, classification, pathogenesis, and clinical significance.Rapamycin-treated human endothelial cells preferentially activate allogeneic regulatory T cells.Allorecognition and the alloresponse: clinical implications.Can mTOR inhibitors reduce the risk of late kidney allograft failure?Immune tolerance: mechanisms and application in clinical transplantation.The Emerging Role of Interleukin-21 in Transplantation.GRIM19 ameliorates acute graft-versus-host disease (GVHD) by modulating Th17 and Treg cell balance through down-regulation of STAT3 and NF-AT activation.Down-regulating cyclin-dependent kinase 9 of alloreactive CD4+ T cells prolongs allograft survival.Standardization and cross validation of alloreactive IFNγ ELISPOT assays within the clinical trials in organ transplantation consortiumTransplant acceptance following anti-CD4 versus anti-CD40L therapy: evidence for differential maintenance of graft-reactive T cells.Hyperlipidemia Promotes Anti-Donor Th17 Responses That Accelerate Allograft Rejection.Hyperlipidemia Alters Regulatory T Cell Function and Promotes Resistance to Tolerance Induction Through Costimulatory Molecule Blockade.Characterization of the fetal blood transcriptome and proteome in maternal anti-fetal rejection: evidence of a distinct and novel type of human fetal systemic inflammatory response.HVEM/LIGHT/BTLA/CD160 cosignaling pathways as targets for immune regulation.Role of T cells in graft rejection and transplantation tolerance.Biomarkers for the diagnosis of acute cellular rejection in liver transplant recipients: A review.Impact of hyperlipidemia on alloimmunity.Identification of novel Interleukin-2 inhibitors through computational approaches.Influence of pro- and anti-inflammatory cytokines in Th1 polarization after allogeneic stimulation.Role of interleukin-17A in early graft rejection after orthotopic lung transplantation in mice.
P2860
Q33187036-522F977E-921D-4AF8-A5F8-7C6E9346D58FQ33205084-D98876F0-14F2-4A26-87B5-8E8D9560126DQ33732470-648B3AE8-C517-4441-8D74-0D9DC41D6FC0Q33822254-CEB1838D-B136-4C07-8B9B-86E12B3090BAQ33845963-B449FE8C-7F3D-4EF9-834F-8EF734A6C0E4Q33882677-7D8444CF-40C5-4E27-BE5F-D178F8DC757CQ34004087-8C8EBBFB-1D64-4FCD-BD2A-6C526EBC87CAQ34072846-7ACECD08-F941-42AD-9C89-02FD39540A0BQ34133012-8A5C224C-D856-4082-BA5B-2CEEA37532F0Q34333949-FF1EE941-A93F-4A0D-9B95-189DBDC659B6Q34639744-32A3A673-3BC4-473B-92BC-BFA5D9173A59Q34922333-B4D7140A-C64D-40D5-B550-D66B68460A79Q35022593-3D3DF0BE-405B-4A35-B307-554E55C980E2Q35094243-7C820D30-B0C0-4F38-A902-743148D6B3B1Q35145260-C9606435-749D-4B5F-8254-21783B49C33EQ35541507-4C97E649-2EB1-4F54-9785-6FE91E447E9DQ35583498-D38A1844-E1BE-43E7-AE91-CAB1906D66F7Q35583526-3EE08E4B-2B7B-4A66-83E2-16078932FA06Q36179184-2BA02AB3-BC26-4055-B2FC-FBA269A72200Q36623201-5A1586AF-E896-4509-9001-FC02F5470576Q36663036-E11F8377-877B-4C54-A6B9-136A2B94DECFQ36733476-3D82B22E-D5B4-4A1F-B497-E8FEB5C61E03Q36820105-5D246205-09F1-4587-922D-217BBDC10A02Q36884566-FFB95B09-5473-4FF6-9981-15024C55187EQ36909564-5CB15810-5F0F-4139-97F9-B6B245937E46Q36975554-E80E0C99-BB37-4AE2-9A23-86B8A6540BA2Q37080218-9BD654D6-93BD-4040-8606-A9B7F4BA814EQ37295249-E446D074-A0C9-4B3A-8F21-38BF5A12175CQ37339632-8C2F2BC1-095B-423E-B86B-054776E87743Q37359067-C0709ADB-B1DF-4765-9830-2392FAF5E9EAQ37444398-CD4E5BF2-292B-4CA6-9406-D07F7BE774F6Q37444403-7BA58075-A081-485E-8F25-BA67582EA616Q37612440-69E88E86-A79A-4D62-B443-4D14F8032195Q37652960-07519299-C5B1-4DA4-A827-28A142A806BCQ37729059-5E2652FB-F490-4023-8607-CC8098E52C72Q38062935-0AF80A52-54B8-476C-94A7-1EF5C157BB49Q39041394-02717C41-5CB9-4D9A-A8FA-E916FF880207Q39180930-620584FC-D63D-47EC-AC5B-BB39F37336DBQ39522836-A2BC4F83-900D-4758-8DAC-7E855A9EC2B0Q39689040-7DBC8A4A-69D2-45E2-8A4A-30C63831A7A0
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Multiple pathways to allograft rejection.
@ast
Multiple pathways to allograft rejection.
@en
Multiple pathways to allograft rejection.
@nl
type
label
Multiple pathways to allograft rejection.
@ast
Multiple pathways to allograft rejection.
@en
Multiple pathways to allograft rejection.
@nl
prefLabel
Multiple pathways to allograft rejection.
@ast
Multiple pathways to allograft rejection.
@en
Multiple pathways to allograft rejection.
@nl
P2093
P1433
P1476
Multiple pathways to allograft rejection.
@en
P2093
Alain Le Moine
Daniel Abramowicz
Michel Goldman
P304
P356
10.1097/00007890-200205150-00001
P577
2002-05-01T00:00:00Z